<DOC>
	<DOCNO>NCT01467401</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate efficacy safety biphasic insulin aspart ( NovoMix®30 ) biphasic human insulin ( Mixtard® 30 ) subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety NovoMix® 30 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes least 24 month Insulin treatment pase 3 month HbA1c ( glycosylated haemoglobin ) 13 % BMI ( Body Mass Index ) 40 kg/m^2 Ability willingness perform selfblood glucose monitoring Receipt investigational drug within 4 week prior trial Treatment OHAs ( Oral Hypoglycaemic Agents ) within 4 week prior trial Total daily insulin dosage less equal 1.8 IU/kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>